Kishan Govind, MD
Ophthalmology · Aiken, SCNPI 1740542893
Payments from drug & device makers
Across 288 payments — averaging $38.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Notal Vision, Inc.$6K
- Alimera Sciences, Inc.$2K
- Genentech USA, Inc.$914
- Regeneron Healthcare Solutions, Inc.$603
- Apellis Pharmaceuticals, Inc.$515
- Astellas Pharma US Inc$443
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$1,20023%
- Food & beverage$3,97777%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Notal Vision, Inc. | 166 | $6,142 |
| Alimera Sciences, Inc. | 12 | $1,522 |
| Genentech USA, Inc. | 23 | $914 |
| Regeneron Healthcare Solutions, Inc. | 23 | $603 |
| Apellis Pharmaceuticals, Inc. | 10 | $515 |
| Astellas Pharma US Inc | 14 | $443 |
| AbbVie(2 entities) | 9 | $163 |
| Mallinckrodt Hospital Products Inc. | 5 | $109 |
| Heidelberg Engineering, Inc. | 1 | $105 |
| Genentech, Inc. | 1 | $91 |
| Regeneron | 1 | $84 |
| Novartis | 4 | $74 |
| Bausch & Lomb Americas Inc. | 3 | $74 |
| Coherus Oncology, Inc. | 2 | $55 |
| Eyepoint US, Inc. | 3 | $55 |
| Biogen | 2 | $47 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $46 |
| Amgen | 2 | $38 |
| Maculogix, Inc. | 2 | $33 |
| Sandoz | 1 | $26 |
| Harrow Eye, LLC | 1 | $25 |
| Aerie Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,177 in reported general payments places this provider in the 80th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketorolac Tromethamine | 115 | $4,188 |
| Prednisolone Acetate | 71 | $4,077 |
| ValacyclovirValacyclovir Hcl | 19 | $1,718 |
| Brimonidine Tartrate | 15 | $606 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 22 | $231 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Aiken
- Anthony GreerAiken$37K
- John WellsWest Columbia$7.1M
- William ClarkWest Columbia$6.2M
- Daniel AlfaroCharleston$4.6M
- Kerry SolomonMt Pleasant$4.6M
- Eric JablonCharleston$1.2M
- George WaringMt Pleasant$1M
- John KerrisonCharleston$975K
- Karolinne RochaCharleston$799K
- John PayneWest Columbia$574K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.